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COMPARISON OF CHANGES IN SERUM PROSTATE SPECIFIC ANTIGEN IN 
PROSTATE CANCER PATIENTS TREATED EITHER WITH FLUTAMIDE OR 
STILBOESTROL MONOTHERAPY.
ABSTRACT
Prostate cancer is a disease of males. Though commoner in the elderly, cases are beginning to be reported in the younger population. It is the 
commonest cancer diagnosed in males. Risk factors include ageing, genetic/familial factors, racial predilection, increased fat diet, and 
hormonal imbalance. It is a slow-growing tumour but can be associated with severe morbidity. The commonest histologic type is 
adenocarcinoma (>95%). When detected early, cure may be possible. Prostate-specific antigen (PSA) is the major serum marker used to 
monitor progress of the disease and its' response to therapy. Several treatment modalities have been used in the management of prostate 
cancer. This includes watchful waiting, prostatectomy, radiotherapy, hormone therapy, and chemotherapy. These treatment options are not 
without devastating and sometimes life-threatening adverse effects; hence the choice of therapy depends on patient's age, stage of disease, 
other co-morbidities, and even patient's choice.  
AIMS AND OBJECTIVE: This study aimed at establishing the variation in PSA among patients with advanced CaP treated either with Flutamide 
or Stilboestrol monotherapy in UCTH, Calabar. This helped in choosing an agent with better patient compliance, better therapeutic effect, 
minimal side-effects, and cost-effectiveness.
METHOD: All newly diagnosed prostate cancer patients in the Division of Urology, Department of Surgery, UCTH, Calabar that met certain 
inclusion criteria were treated either with Flutamide or Stilboestrol monotherapy over a period of one year. Patients enrolled into the study 
were shared into two equal groups based on certain considerations. Response to therapy was monitored by conducting a three-monthly PSA 
check and results from the groups compared.
RESULTS: Fifty patients were enrolled into the study. The mean age was 70.12±8.93, and age range was 51-93 years. The peak age range was 
61-70 years constituting 40.0% of total number of patients. The decline in serum PSA caused by flutamide and stilboestrol during each quarter 
of the year was 8.0%, 12.0%, 12.0%, 4.0% and 28.0%, 4.0%, 28.0%, 4.0% respectively. Overall flutamide caused a 36.0% reduction and 
stilboestrol 64.0% reduction in serum PSA over the period. In all, stilboestrol caused a greater decline in serum PSA compared to flutamide, and 
this became statistically significant at 9 months (p=0.044) and one year (p=0.048) of therapy.
CONCLUSION: Patients who are on androgen deprivation therapy for CaP have their serum PSA reduced by either flutamide or stilboestrol 
monotherapy. However, over time, the PSA is more rapidly reduced by stilboestrol monotherapy compared to flutamide monotherapy.
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he prostate gland is the male organ most commonly 
afflicted with either benign or malignant 
1neoplasms . Prostate cancer (CaP) is the most T
2common cancer in men . It is the second leading cause of 
1,3cancer death for men in North America . In Nigeria, it is 
4,5the most commonly diagnosed cancer in men . An 
estimated hospital prevalence of 127 per 100,000 was 
6reported in 1997 in Lagos, Nigeria . The incidence 
continues to increase with advancing age.  Of all cancers, 
1the prevalence of CaP increases the most rapidly with age . 
The lifetime risk of a 50-year-old man for latent CaP 
(detected as an incidental finding at autopsy, not related to 
the cause of death) is 40%; for clinically apparent CaP, 
19.5%; and for death from CaP, 2.9% . Thus many prostate 
cancers are indolent and inconsequential to the patient 
while others are virulent, and if detected too late or left 
untreated, may result in a patient's death. 
Various treatment modalities are used in the management 
of CaP. This include androgen deprivation therapy (ADT), 
corticosteroids, radiotherapy, chemotherapy, and surgery. 
Stilboestrol (also called diethylstilboestrol-DES) and 
flutamide are some agents that have been used mostly in 
treatment of advanced CaP. Though at physiologic levels 
oestrogens do not have direct effect on prostate cancer, 
exogenous oestrogens block the hypothalamic steroid 
receptor and inhibit the release of luteinizing hormone-
releasing hormone (LHRH) leading to below castrate 
levels of testosterone. It also has cytotoxic effects on the 
7tumour cells . Diethylstilboestrol at 1-3mg/day reduces 
testosterone to castrate levels {0.7-1.7nmol/l (0.2-
7,80.5ng/ml)} . DES is associated with increased incidence of 
cardiovascular-related deaths. Risk of cardiovascular 
disease increase with age, weight >75kg and a history of 
9cardiovascular disease . Other side-effects include nausea, 
fluid retention, ankle oedema, hypertension, heart failure, 
thromboembolic disease, testicular atrophy, loss of libido, 
INTRODUCTION
 1 1 2 31  2Otobo O.F, Ekwere, P.D, Nkposong E.O., Omoruyi K, Ugbem T, 3Eyam E.E
1Division of Urology, Department of Surgery, University of Calabar Teaching Hospital, Calabar, Nigeria.
2Department of Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria.
3Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria
Correspondence to : 
Dr Otobo, O.F
Division of Urology, Department of Surgery, 




Nigerian Journal of Medicine, Vol. 29 No. 1 January - March 2020 ISSBN 1115-2613
impotence, gynecomastia, and nipple pigmentation.  
Flutamide is a pure anti-androgen that blocks the effects of 
androgen at the target organs and the brain. It initially 
increases the blood levels of testosterone, luteinizing 
hormone (LH), and oestradiol. Its administration can lead 
to painful gynecomastia, decreased libido and potency, 
7nausea, vomiting, diarrhoea, and hepatitis-like syndrome . 
This study is aimed at comparing PSA changes in prostate 
cancer patients treated either with stilboestrol or flutamide 
monotherapy.
PATIENTS AND METHODS
This was a prospective observational study that was 
carriedout over a period of one year from July 2016 to June 
2017. Ethical approval was gotten from the Hospitals' 
Health Research Ethics Committee.
INCLUSION CRITERIA
1. All newly histologically diagnosed primary advanced
prostate cancer patients in UCTH, Calabar.
2. All newly diagnosed primary localized prostate cancer
patients who opted for/were placed on ADT for various 
reasons.
3. All of number one above placed either on flutamide or
stilboestrol monotherapy
4. All of number one above not on any other form of
therapy for BPH or CaP.
EXCLUSION CRITERIA
1. Prostate cancer (CaP) patients already on any treatment
modality
2. CaP patients who were not treated with flutamide or
stilboestrol monotherapy
3. CaP patients placed on more than one form of therapy
4. CaP patients whose histologic diagnosis was done
outside UCTH
5. CaP patients whose therapy were changed during the
course of the study
6. CaP patients with poor drug compliance were removed
from the study
7. CaP patients who opted for non-hormonal treatment
8. Patients with secondaries from other sites to the prostate
gland 
An investigator-administered proforma was designed to 
record details of patient's personal and clinical data as well 
as findings from relevant investigations.
Every patient seen at the Urology clinic of UCTH with 
complaints of Lower Urinary Tract Symptoms (LUTS) 
relevant to CaP was 'clerked' and examined in accordance 
with the proforma for the study. A careful clinical 
examination with emphasis on digital rectal examination 
(DRE) was carried out on each patient. Patients received 
counselling on the possible pathology and the 
management options. Following DRE, patients with 
suspicious findings were requested to do serum PSA and 
trans-rectal ultrasound scan. Those whose scans showed 
heterogenous (hypoechoic or hyperechoic) echotexture, 
distorted prostate capsule, were counselled for prostate 
biopsy. For each candidate, about 6-12 prostate biopsy 
samples were collected into a container of Bouin's solution 
and sent with a well-filled histopathology request form to 
the Histopathology laboratory of UCTH for analysis. 
Patients whose histopathology reports were positive for 
primary prostate cancer and qualified for treatment had 
counselling for the various treatment options available. 
Those who chose hormonal therapy received further 
counselling for either flutamide or stilboestrol 
monotherapy. Those who weighed ?75kg, and/or had 
cardiovascular/risk of cardiovascular diseases were 
p l a c e d  o n  f l u t a m i d e  w h i l e  t h o s e  w i t h  
paraparesis/paraplegia (being a sign of spinal deposits) 
were placed on stilboestrol. This was done until equal 
number of persons were recruited into each group. 
Flutamide was administered orally at 250mg 8-hourly and 
DES orally at 1mg daily for at least 32 weeks as was the 
protocol of the Urology Division. Patients were told of the 
possible side-effects of each medication, asked to adhere 
strictly to the prescription, and report any adverse event to 
the clinic. Patients were also told to present the 
medications being taken at each clinic visit and asked to 
describe how they were being taken to confirm adherence. 
They were asked to do a three monthly check on serum 
PSA for follow up of response to treatment as was the 
protocol of the Urology Division of UCTH, Calabar. 
Patients were given the requisite investigation form, 
stating the times of follow-up tests and visits. Where 
possible, they were contacted via phone calls to remind 
them of their follow-up visits.  At each visit, each patient 
had his vital signs and relevant anthropometry checked, 
interviewed on drug compliance, side effects, and 
counselled on progress made before the next appointment 
was given. 
The change in the PSA of those treated with flutamide only 
were then compared with those treated with stilboestrol 
only.  All  the participants in the study had 
adenocarcinoma.
STATISTICAL ANALYSIS
Data analysis was done using the Statistical Package for 
Social Sciences (SPSS) version 20. Frequencies, 
percentages, means, and standard deviation were used to 
summarize the data. Relevant tests of significance such as 
2the Chi-square (x ) and T-test were conducted at a 
confidence limit of 95% and a P-value of <0.05.  Data were 
presented in tables, charts, and figures. 
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RESULTS  
Table 1: Socio-demographic characteristics f patients who received either Flutamide or Stilboestrol 
monotherapy for cancer of the prostate (N=50). 
Overall, a proportion of 74.0% of patients belonged to the 61 to 80 years age group. In the flutamide group,  this 61-80 year 
age group accounted for 72.0% compared with a slightly higher proportion of 76.0% in the stilboestrol group. The difference 
by age between the two arms was not statistically significant (p=0.323). 











51-60 5(20.0) 2(8.0) 7(14.0) 4.673 0.323
61-70 12(48.0) 8(32.0) 20(40.0)
71-80 6(24.0) 11(44.0) 17(34.0)







Mean age±SD 67.76±8.66 72.48±9.74 70.12±8.93 1.918* 0.061
Marital status







2(8.0) 5(20.0) 7(14.0) 1.906 0.409
Secondary 8(32.0) 9(36.0) 17(34.0)
Tertiary 15(60.0) 11(44.0) 26(52.0)
Tribe
Efik 8(32.0) 8(32.0) 16(32.0) 2.889 0.717
Annang 3(12.0) 6(24.0) 9(18.0)
Ibibio 2(8.0) 1(4.0) 3(6.0)
Ekoi 7(28.0) 7(28.0) 14(28.0)




24(96.0) 25(100.0) 49(98.0) 1.407 0.236
Traditional 1(4.0) 0(0.0) 1(2.0)
*=T-test statistic
 
 Figure 1: Comparison Of Pre-Treatment PSAs Among CaP Patients Treated Either With Flutamide Or 
Stilboestrol Monotherapy.
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Figure 4: Proportion of CaP patients with normal or elevated serum PSA at different 
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DISCUSSION
Over  the  years ,  e i ther  pure  ant i -androgens  
10(flutamide/bicalutamide)  or stilboestrol monotherapy 
has been used in the treatment of advanced primary 
11carcinoma of the prostate . However, no comparison has 
been made as regards the efficacy of one over the other. 
This study was aimed at bringing to lime-light such 
differences in their efficacy if any. 
In a study carriedout earlier in UCTH, Calabar by Ekwere et 
12al. (2002), a mean age of 66.6±9.8 years was obtained . 
Another study carried out in UCTH (2003), Calabar gave a 
13mean age of 66.9±10.1 years . Ojewola et al.had in a similar 
study done in Lagos reported a mean age of 66.9±10.7 with 
14a peak of 61-70 years . These correlate strongly with our 
findings in this study, thus re-affirming the knowledge 
that CaP is commoner in the older age group.
The commonest LUTS was urinary frequency (50.0%) 
followed by nocturia (42.0%). This correlates with a study 
by Glasser et al. who had reported that storage symptoms 
15were commoner than voiding symptoms .
Gynaecomastia (22.0%) was the commonest complication 
of treatment among patients who participated in this 
study. This was, however, commoner among the flutamide 
group (32.0%) compared to the stilboestrol group (12.0%). 
Ekwere PD had reported same as an important adverse 
reaction following high dose stilboestrol (15mg three times 
16per day) use in prostate cancer patients .
There was no significant difference in the pre-treatment 
PSAs among the two groups.
Denis et al. had reported a 90.0% decline in serum PSA 
17following androgen withdrawal therapy . This is in 
keeping with studies by Smith et al.and Serrate et al. who 
reported 43.0% and >50.0% decline respectively in serum 
18, 19PSA of CaP patients treated with DES . Domenico et 
al.had also reported ≥ 50.0% reduction of total PSA in 
826.0% to 66.0% of patients with CRPC .
From the study, either flutamide or stilboestrol 
monotherapy were noted to cause a reduction in the serum 
PSA of CaP patients with flutamide causing a lower 
reduction (36.0%) compared with stilboestrol  that caused 
64.0% reduction over the period. Up to 6 months, the 
difference in percentage changes between the serum PSA 
Table 2: Comparison Between Serum PSA Among Cap Patients Treated With Either Flutamide Or Stilboesterol 
Monotherapy Over A Period Of One Year (N=50)  
   Drug administered









Chi square test p-value
Before drug administration
Normal 0(0.0) 0(0.0) 0(0.0) -- --
Elevated 25(50.0) 25(50.0) 50(100.0)
3 months after drug 
administration
Normal 2(22.2) 7(77.8) 9(100.0) Fisher’s Exact** 0.138
Elevated 23(56.1) 18(43.9) 41(100.0)
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among the 2 groups was not statistically significant 
(p>0.05). After 9 months (with those having normal levels 
of PSA increasing), the percentage changes remained 
higher in the stilboestrol group when compared with the 
arm that received flutamide (60.0 % versus 32.0%), and the 
difference became statistically significant (p<0.05). 
Similarly, after 12 months, more of those that received 
stilboestrol compared with those who received flutamide 
had normal PSA values (64.0% versus 36.0%). Again, the 
difference in percentage change was statistically 
significant (p<0.05). 
Over the period of this study (at each measurement), it was 
also noted that the total percentage reduction of serum 
PSA among those that were on stilboestrol was 
consistently higher compared to those that were placed on 
flutamide. This difference, however, was not statistically 
significant until after 9 months of therapy and beyond 
(p=0.044 at 9 months and p= 0.048 at 12 months). 
Thus, there is a statistically significant difference in the 
change in the serum PSA of CaP patients treated either 
with flutamide or stilboestrol monotherapy over time. 
Some limitations of this study include poor drug 
compliance by some patients, paucity of funds to procure 
medications and do relevant follow-up investigations, 
poor compliance with clinic appointments and change of 
therapy during the course of treatment due maybe to 
development of resistance 
CONCLUSION 
This study has shown that either flutamide or stilboestrol 
monotherapy can cause a decline in the serum PSA of CaP 
patients. The percentage decline, however, vary among the 
two drugs; being higher among the stilbesterol group. 
However, this change became statistically significant after 
9 months and 12 months of therapy. 
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